White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
A unique, wide-ranging survey of originator pharmaceutical companies by Thomson Reuters found that commercial professionals either consider there is nothing they can do to prevent sales erosion by generic drugs, or assume that the problem is being dealt with by somebody else in their organization. In this white paper, Thomson Reuters exposes these and other myths about generic competition, and shows what originators can do to predict its likely timing, source, and intensity.
D003625:Data Collection; D004345:Drug Industry / Q000191:economics* / Q000379:methods*; D016568:Drugs, Generic / Q000191:economics*; D004465:Economic Competition; D006801:Humans; D007255:Information Services; D010330:Patents as Topic; D017149:Private Sector / Q000191:economics
D016568:Drugs, Generic